Learn about Type I Polyglandular Autoimmune Syndrome, an incredibly rare autoimmune disorder often characterized by inefficiencies in the adrenal gland.
Programa Congreso Para Todos
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015.XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai: 2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Learn about Type I Polyglandular Autoimmune Syndrome, an incredibly rare autoimmune disorder often characterized by inefficiencies in the adrenal gland.
Programa Congreso Para Todos
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015.XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai: 2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Monomeric allergoid: the new advances of AIT, in only one product. Dr. Enrico...Juan Carlos Ivancevich
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Journal club covid vaccine neurological complications ZIKRULLAH MALLICK
the risks of adverse neurological events following SARS-CoV-2 infection are much greater than those associated with vaccinations, highlighting the benefits of ongoing vaccination programs.
Confirmation of Safety of COVID 19 mRNA Vaccination for Cancer Patientsijtsrd
Patients in the active phase of treatment for cancer are a population at risk of coronavirus disease 19 COVID 19 with poor prognosis. While a majority of patients treated for cancer expressed their will to be vaccinated as early as December 2020 in a French survey, no data were available in terms of vaccine efficacy and tolerance, because they were excluded from initial registration trials. Several clinical facilities aimed to assess the safety and immunogenicity of the BNT162b2 Pfizer–BioNTech vaccine in patients with cancer. In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. However, the anti SARS CoV 2 immune response was lower in patients with solid tumors who were vaccinated a second dose of BNT162b2 vaccine than in healthy individuals. These data support prioritization of patients with cancer for an early day 21 second dose of the BNT162b2 vaccine. Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi "Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd42563.pdf Paper URL: https://www.ijtsrd.commedicine/other/42563/confirmation-of-safety-of-covid19-mrna-vaccination-for-cancer-patients/takuma-hayashi
World Allergy Week 2015: AIRWAY ALLERGIES The human and economic burdenJuan Carlos Ivancevich
Welcome! Join us during World Allergy Week 2015 and increase awareness of Airway Allergies - A Human and Economic Burden. There are many ways you can participate, and we hope you will explore this website, returning often, as it will continue to change.
The World Allergy Organization (WAO) is addressing the need for greater awareness and understanding of allergy topics as well as the exchange of ideas and collaboration in order to address treatment and quality-of-life issues related to the care of patients with allergic rhinitis and asthma.
Infectious diseases are the second most common cause of death in end-stage renal disease (ESRD) patients. Patients with ESRD are at high risk for several infections, due to exposure to blood products and frequent dialysis. The increased susceptibility to infections among these patients is indicative of a complex and varied state of immunodeficiency manifested by abnormal phagocytosis, T and B lymphocytes abnormalities and impaired response to T cell dependent pathogens such as hepatitis B and influenza viruses. These immunologic abnormalities are complicated by the use of immunosuppressive drugs used to treat and control underlying disease and exacerbated by nutritional deficiency and the dialysis procedure. Though many of these infections can be prevented by appropriate vaccination, the usual schedules of vaccination may be less effective.
The aim of this paper is to review the studies on the use of vaccines in ESRD patients
and summarize the vaccines required in this population.
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Monomeric allergoid: the new advances of AIT, in only one product. Dr. Enrico...Juan Carlos Ivancevich
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Journal club covid vaccine neurological complications ZIKRULLAH MALLICK
the risks of adverse neurological events following SARS-CoV-2 infection are much greater than those associated with vaccinations, highlighting the benefits of ongoing vaccination programs.
Confirmation of Safety of COVID 19 mRNA Vaccination for Cancer Patientsijtsrd
Patients in the active phase of treatment for cancer are a population at risk of coronavirus disease 19 COVID 19 with poor prognosis. While a majority of patients treated for cancer expressed their will to be vaccinated as early as December 2020 in a French survey, no data were available in terms of vaccine efficacy and tolerance, because they were excluded from initial registration trials. Several clinical facilities aimed to assess the safety and immunogenicity of the BNT162b2 Pfizer–BioNTech vaccine in patients with cancer. In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. However, the anti SARS CoV 2 immune response was lower in patients with solid tumors who were vaccinated a second dose of BNT162b2 vaccine than in healthy individuals. These data support prioritization of patients with cancer for an early day 21 second dose of the BNT162b2 vaccine. Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi "Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd42563.pdf Paper URL: https://www.ijtsrd.commedicine/other/42563/confirmation-of-safety-of-covid19-mrna-vaccination-for-cancer-patients/takuma-hayashi
World Allergy Week 2015: AIRWAY ALLERGIES The human and economic burdenJuan Carlos Ivancevich
Welcome! Join us during World Allergy Week 2015 and increase awareness of Airway Allergies - A Human and Economic Burden. There are many ways you can participate, and we hope you will explore this website, returning often, as it will continue to change.
The World Allergy Organization (WAO) is addressing the need for greater awareness and understanding of allergy topics as well as the exchange of ideas and collaboration in order to address treatment and quality-of-life issues related to the care of patients with allergic rhinitis and asthma.
Infectious diseases are the second most common cause of death in end-stage renal disease (ESRD) patients. Patients with ESRD are at high risk for several infections, due to exposure to blood products and frequent dialysis. The increased susceptibility to infections among these patients is indicative of a complex and varied state of immunodeficiency manifested by abnormal phagocytosis, T and B lymphocytes abnormalities and impaired response to T cell dependent pathogens such as hepatitis B and influenza viruses. These immunologic abnormalities are complicated by the use of immunosuppressive drugs used to treat and control underlying disease and exacerbated by nutritional deficiency and the dialysis procedure. Though many of these infections can be prevented by appropriate vaccination, the usual schedules of vaccination may be less effective.
The aim of this paper is to review the studies on the use of vaccines in ESRD patients
and summarize the vaccines required in this population.
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
"What Will It Take To Control TB?" Richard Chaisson, MDUWGlobalHealth
Dr. Richard Chaisson, Professor of Medicine, Epidemiology and International Health and Director of the Center for Tuberculosis Research at the Johns Hopkins University in Baltimore was the keynote Jan. 19 as part of the Washington Global Health Discovery Series. His talk was on ""What Will It Take To Control TB?"
NCCR 2020: Conference Of Very Important Disease (COVID-19) | 24 - 26 August 2020
Young Investigator Awards Presentation
Wan Shakira Bt Rodzlan Hasani
(Institute for Public Health, NIH)
https://doi.org/10.5281/zenodo.4004583
"Covid-19" A world wide pandemic. Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus.
Most people who fall sick with COVID-19 will experience mild to moderate symptoms and recover without special treatment. However, some will become seriously ill and require medical attention
Interstitial lung disease (ILD) is a common complication of scleroderma that leads to inflammation and scarring of the lungs. In this session, we will review the prevalence of scleroderma-associated ILD (SSc-ILD), classic symptoms, and the approach to evaluating patients with suspected disease. In addition, we will cover various treatments available for patients with SSc-ILD.
This talk was presented at the Scleroderma Patient Education Conference on May 4, 2024, hosted by the Scleroderma Foundation of Greater Chicago.
For more info about scleroderma and the foundation, head to www.stopscleroderma.org
Influenza vaccination and prevention of antimicrobial resistance - Slides by ...WAidid
The lecture presented by Professor Susanna Esposito at AMR 2019 on influenza vaccination and abuse of available antimicrobials.
To learn more, please visit www.waidid.org.
Fact and Opinion about COVID-19 outbreakteguhfirdaus1
Name : Teguh Firdaus
NIM : 20190900015
Major : Industrial Engineering
Faculty : Science and Technology
Courses : Bahasa Inggris 2
Lecturer : Harisa Mardiana
FInal Exam
Similar to WAO "Special Session - in View of WISC 2020: Allergy and COVID" (20)
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
WAO "Special Session - in View of WISC 2020: Allergy and COVID"
1.
2.
3. Announcing a special WISC 2020 Pre-Conference Event "Allergy and COVID-19"
4 June 2020 Time: 6:00-10:30 EDT/ 12:00-16:30 CEST/ 19:00-23:30 JST
INTRODUCTION
Motohiro Ebisawa
COVID-19: A DISEASE THAT KNOWS NO BORDERS
Bryan Martin
DISCUSSION
Sandra Gonzalez-Diaz
COULD ALLERGY PROTECT FROM COVID-SARS2 INFECTION?
Daniel J Jackson
DISCUSSION
Alessandro Fiocchi
IMMUNOPATHOGENESIS OF COVID-SARS2 INFECTION
Rita Carsetti
DISCUSSION
José Antonio Ortega-Martell
ADVISE POLITICIANS IN A PANDEMICERA: THE ITALIAN GOVERNMENTAL
COVID TASK FORCE EXPERIENCE
Alberto Villani
DISCUSSION
Peter Hellings
MANAGING ALLERGIC RHINITIS IN COVID-19-SARS2 ERA
Jean Bousquet
DISCUSSION
Philip W. Rouadi
MANAGING ASTHMA IN COVID-19-SARS2 ERA
Michael Levin
DISCUSSION
Gary Wong
MANAGING BIOLOGICS IN COVID-19-SARS2 ERA
Mario Morais-Almeida
DISCUSSION
Jonathan A. Bernstein
HANDLING OF ALLERGEN IMMUNOTHERAPY IN THE COVID-19 PANDEMIC
Ignacio Ansotegui
DISCUSSION
Gianni Passalacqua
PANDEMIC CONTINGENCY PLANNING FOR YOUR ALLERGY AND
IMMUNOLOGY CLINIC
Dana Wallace
DISCUSSION
David Peden
HOW TO RUN AN ACADEMIC ALLERGY UNIT DURING COVID-19 PANDEMIC
Giacomo Malipiero
DISCUSSION
Walter Canonica
CONCLUSION
Motohiro Ebisawa
6:00-EDT/12:00-CEST/19:00-JST7:00-EDT/13:00-CEST/20:00-JST
9:00-EDT/14:00-CEST/22:00-JST8:00-EDT/14:00-CEST/21:00-JST10:00-/16:00-/23:00-
5. Symptoms of Coronavirus
https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
• Anyone can have mild to severe symptoms.
• Older adults and people who have severe underlying medical
conditions like heart or lung disease or diabetes seem to be at
higher risk for developing more serious complications from COVID-
19 illness.
What you need to know
People with COVID-19 have had a wide range of symptoms reported –
ranging from mild symptoms to severe illness.
Symptoms may appear 2-14 days after exposure to the virus. People
with these symptoms may have COVID-19:
Watch for symptoms
• Fever or chills
• Cough
• Shortness of breath or difficulty breathing
• Fatigue
• Muscle or body aches
• Headache
• New loss of taste or smell
• Sore throat
• Congestion or runny nose
• Nausea or vomiting
• Diarrhea
Look for emergency warning signs* for COVID-19. If someone is showing
any of these signs, seek emergency medical care immediately
• Trouble breathing
• Persistent pain or pressure in the chest
• New confusion
• Inability to wake or stay awake
• Bluish lips or face
*This list is not all possible symptoms. Please call your medical provider for
any other symptoms that are severe or concerning to you.
Call 911 or call ahead to your local emergency facility: Notify the operator
that you are seeking care for someone who has or may have COVID-19.
When to Seek Emergency Medical Attention
6. How to Protect Yourself & Others
https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html
There is currently no vaccine to prevent coronavirus disease 2019
(COVID-19).
The best way to prevent illness is to avoid being exposed to this virus.
The virus is thought to spread mainly from person-to-person.
• Between people who are in close contact with one another
(within about 6 feet).
• Through respiratory droplets produced when an infected person
coughs, sneezes or talks.
• These droplets can land in the mouths or noses of people who
are nearby or possibly be inhaled into the lungs.
• Some recent studies have suggested that COVID-19 may be
spread by people who are not showing symptoms.
Wash your hands often
Everyone Should
Cover coughs and sneezes
Cover your mouth and nose with a
cloth face cover when around others
Avoid close contact
Clean and disinfect
Monitor Your Health
Know how it spreads
7. Lu CW, Liu XF & Jia ZF (2020): 2019-nCoVtransmission through
the ocular surface must not be ignored. Lancet395: e39.
8. Numbers and percentages of comorbidity in patients with Covid-19
Region
Number of
Covid-19
patients
Mean or
median
age (y)
Numbers of comorbid patients (%)* Regional
asthma
prevalence
Reference
Asthma COPD Diabetes
China
Wuhan 140 57 0 (0) 2 (1.4) 17 (12.1) 6.4%a Zhang JJ, et al. 2020
Wuhan 548 60 5 (0.9) 17 (3.1) 83 (15.1) 6.4%a Li X, et al. 2020
Whole 1590 48.9 0 (0) 24 (1.5) 130 (8.2) 6.4%a Guan WJ, et al. 2020
USA
Georgia 305 60 32 (10.5) 16 (5.2) 121 (39.7) 7.7%b Gold JAW et al. 2020
California 54 53.5 3 (0.6) 0 (0) 11 (20.4) 7.7%b Rubin SJS, et al. 2020
New York 5700 63 513 (9) 308 (5.4) 1927 (33.8) 7.7%b Richardson S, et al. 2020
New York 1651 50 99 (6) 66 (4) 248 (15.0) 7.7%b Singer AJ, et al. 2020
Mexico Whole 7497 46 270 (6) 202 (2.7) 1252 (16.7) 8.7%c Solís P, et al. 2020
Total 17485 922 (5.3)† 635 (3.6) 3789 (21.6) 8.0%
* The numbers of patients were calculated only if the total numbers of patients and percentages were presented.
Regional asthma prevalence data are cited from aLancet. 2019;394(10196):407-18; and bCDC, 2020. Most recent national asthma data. Available at:
http://www.cdc.gov/asthma/most_recent_national_asthma_data.htm; and cAsthma Res Pract. 2017;3:4.
† p < 0.0001 by Mantel-Haenszel test.
Matsumoto K, Saito H, Does asthma affect morbidity or severity of Covid-19?,
Journal of Allergy and Clinical Immunology (2020) doi: https://doi.org/10.1016/j.jaci.2020.05.017.
9. Association of asthma, COPD and diabetes comorbidity on the severity of Covid-19
Comorbidity+/- (%)
p value*
Total Non-severe Severe
Wuhan, Chinaa 548 279 269
Asthma 5/543 (0.9) 2/277 (0.7) 3/266 (1.1) 0.483
COPD 17/531 (3.1) 4/275 (1.4) 13/256 (4.8) 0.019
Diabetes 83/465 (15.1) 31/248 (11.1) 52/217 (19.3) 0.010
New York, USAb 1651 914 737
Asthma 99/1552 (6.0) 47/867 (5.1) 52/685 (7.1) 0.128
COPD 66/1585 (4.0) 14/900 (1.5) 52/685 (7.1) 0.000
Diabetes 248/1403 (15.0) 49/865 (5.4) 199/538 (27.0) 0.000
Total 2199 1193 1006
Asthma 104/2095 (4.7) 49/1144 (4.1) 55/951 (5.5) 0.111
COPD 83/2116 (3.8) 18/1175 (1.5) 65/941 (6.5) 0.000
Diabetes 331/1868 (15.1) 80/1113 (6.7) 251/755 (25.0) 0.000
*p values were calculated by Fischer’s Exact test, c2 test or Mantel-Haenszel test.
a Li X, et al., J Allergy Clin Immunol 2020 doi: 10.1016/j.jaci.2020.04.006. [Epub ahead of print]
b Singer AJ, et al., Ann Emerg Med 2020 at SSRN: https://ssrn.com/abstract=3583678
Matsumoto K, Saito H, Does asthma affect morbidity or severity of Covid-19?,
Journal of Allergy and Clinical Immunology (2020) doi: https://doi.org/10.1016/j.jaci.2020.05.017.
136. Announcing a special WISC 2020 Pre-Conference Event "Allergy and COVID-19"
4 June 2020 Time: 6:00-10:30 EDT/ 12:00-16:30 CEST/ 19:00-23:30 JST
INTRODUCTION
Motohiro Ebisawa
COVID-19: A DISEASE THAT KNOWS NO BORDERS
Bryan Martin
DISCUSSION
Sandra Gonzalez-Diaz
COULD ALLERGY PROTECT FROM COVID-SARS2 INFECTION?
Daniel J Jackson
DISCUSSION
Alessandro Fiocchi
IMMUNOPATHOGENESIS OF COVID-SARS2 INFECTION
Rita Carsetti
DISCUSSION
José Antonio Ortega-Martell
ADVISE POLITICIANS IN A PANDEMICERA: THE ITALIAN GOVERNMENTAL
COVID TASK FORCE EXPERIENCE
Alberto Villani
DISCUSSION
Peter Hellings
MANAGING ALLERGIC RHINITIS IN COVID-19-SARS2 ERA
Jean Bousquet
DISCUSSION
Philip W. Rouadi
MANAGING ASTHMA IN COVID-19-SARS2 ERA
Michael Levin
DISCUSSION
Gary Wong
MANAGING BIOLOGICS IN COVID-19-SARS2 ERA
Mario Morais-Almeida
DISCUSSION
Jonathan A. Bernstein
HANDLING OF ALLERGEN IMMUNOTHERAPY IN THE COVID-19 PANDEMIC
Ignacio Ansotegui
DISCUSSION
Gianni Passalacqua
PANDEMIC CONTINGENCY PLANNING FOR YOUR ALLERGY AND
IMMUNOLOGY CLINIC
Dana Wallace
DISCUSSION
David Peden
HOW TO RUN AN ACADEMIC ALLERGY UNIT DURING COVID-19 PANDEMIC
Giacomo Malipiero
DISCUSSION
Walter Canonica
CONCLUSION
Motohiro Ebisawa
6:00-EDT/12:00-CEST/19:00-JST7:00-EDT/13:00-CEST/20:00-JST
9:00-EDT/14:00-CEST/22:00-JST8:00-EDT/14:00-CEST/21:00-JST10:00-/16:00-/23:00-